Incomplete protection against hepatitis B among remote Aboriginal adolescents despite full vaccination in infancy
DOI:
https://doi.org/10.33321/cdi.2010.34.42Keywords:
Australia, immunity, hepatitis, HBV, adolescents, Indigenous immunisation coverageAbstract
The objective of this study was to determine long-term immunity to hepatitis B virus (HBV) in a cohort of adolescents who received plasma-derived HBV vaccine in 1989 and 1990 in a remote Australian Aboriginal community. This was done using a serological survey; primary outcome measures were cut-off titres of HBsAb, and the presence of HBcAb and/or HBsAg. Of 37 adolescents in the cohort, 4 (11%) had evidence of active infection, one with abnormal liver enzymes, 7 (19%) had evidence of past infection, 15 (41%) were HBsAb positive in low titre and 11 (30%) were classed as immune. It was concluded that there was relatively poor long-term serological immunity to HBV vaccination in this group; a finding which is in keeping with similar studies in Indigenous and remote populations elsewhere. This finding raises the concern that a significant proportion of Aboriginal adolescents in other remote communities (vaccinated in 1989 and 1990) were not adequately protected by the vaccine. If so, there will be an unexpected burden of chronic HBV infection in these settings and a substantial group who are non-immune, despite having received complete HBV vaccination courses as infants. The authors recommend follow-up serosurveys in remote Aboriginal communities to identify people with low HBsAb titres, especially those without an adequate anamnestic response to another dose of HBV vaccine. In addition, community-based active surveillance programs will be required to detect people with chronic HBV infection and provide access to monitoring and appropriate treatment. Commun Dis Intell 2010;34(4):435–439.
Downloads
References
Blumberg BS. The discovery of the hepatitis B virus and the invention of the vaccine: a scientific memoir. J Gastroenterol Hepatol 2002;17 Suppl:S502–S503.
Hanna JN. Poor response to hepatitis B vaccine administered to aboriginal infants in Central Australia. Med J Aust 1987;146(9):504–505.
Hanna JN, Faoagali JL, Buda PJ, Sheridan JW. Further observations on the immune response to recombinant hepatitis B vaccine after administration to aboriginal and Torres Strait Island children. J Paediatr Child Health 1997;33(1):67–70.
Gardner ID, Wan X, Mathews JD. Hepatitis B in Aboriginal Australians. Todays Life Science 1990;2:16–22.
Wood N. et al. Predictors of HBV immunity in Aboriginal Children: The Australian Aboriginal Birth Cohort Study. J Paediatr Child Health 2008;44(9):A1.
Nelson CM, Wibisono H, Purwanto H, Mansyur I, Moniaga V, Widjaya A. Hepatitis B vaccine freezing in the Indonesian cold chain: evidence and solutions. Bull World Health Organ 2004;82(2):99–105.
Edstam JS, Dulmaa N, Tsendjav O, Dambasuren B, Densmaa B. Exposure of hepatitis B vaccine to freezing temperatures during transport to rural health centers in Mongolia. Prevent Med 2004;39(2):384–388.
Miller NC, Harris MF. Are childhood immunization programmes in Australia at risk? Investigation of the cold chain in the Northern Territory. Bull World Health Organ 1994;72(3):401–408.
Qian Y, Zhang L, Liang XM, Hou JL, Luo KX. Association of immune response to hepatitis B vaccine with HLA-DRB1*02, 07, 09 genes in the population of Han nationality in Guangdong Province. Di Yi Junyi Daxue Xuebao [Chinese] 2002;22(1):67–69.
Wainwright RB, Bulkow LR, Parkinson AJ, Zanis C, McMahon BJ. Protection provided by hepatitis B vaccine in a Yupik Eskimo population—results of a 10-year study. J Infect Dis 1997;175(3):674–677.
Xu H, Zhuang G, Wang X, Chen Q, Chen Z. Efficacy and immune memory of plasma-derived hepatitis B vaccine 11 years after primary immunization. Chung-Hua Yu Fang i Hsueh Tsa Chih [Chinese] 2000;34(2):113–115.
Fitzsimons D, Francois G, Hall A, McMahon B, Meheus A, Zanetta A, et al. Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. Vaccine 2005;23(32):4158–4166.
Bialek SR, Bower WA, Novak R, Helenberger L, Auerbach SB, Williams IT, et al. Persistence of protection against hepatitis b virus infection among adolescents vaccinated with recombinant hepatitis b vaccine beginning at birth: a 15 year follow-up study. Ped Infect Dis J 2008;27(10):881–885.
Australian Government Department of Health and Ageing. Keep it Cool: the Vaccine Cold Chain. Guidelines for Immunisation Providers on Maintaining the Cold Chain. Canberra: Australian Government Department of Health and Ageing; 2001. Available from: http://catalogue.nla.gov.au/Record/2717907 Accessed April 2010.
Samandari T, Fiore AE, Negus S, Williams JL, Kuhnert W, McMahon BJ, et al. Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy. Pediatrics 2007;120(2):373–381.
World Health Organization. Safe vaccine handling, cold chain and immunizations. Geneva: World Health Organization; 1998. Available from: https://www.who.int/vaccines-documents/DocsPDF/www9825.pdf Accessed April 2010.
Moore DJ, Bucens MR, Holman CD, Ott Ak, Wells JL. Prenatal screening for markers of hepatitis B in Aboriginal mothers resident in non-metropolitan Western Australia. Med J Aust 1987;147(11–12):557–558.
Wan X, Currie B, Miller N, Mathews JD. Acute hepatitis B infection in Aboriginal Australians. Aust J Public Health 1993;17:331–333.
Gardner ID, Wan X, Simms PA, Worswick DA, Burrell CJ, Mathews JD. Hepatitis B virus markers in children and staff in Northern Territory schools. Med J Aust 1992;156(9):638–641.
Burrell CJ, Cameron AS, Hart G, Melbourne J, Beal RW. Hepatitis B reservoirs and attack rates in an Australian community. A basis for vaccination and cross infection policies. Med J Aust 1983;2(10):492–496.
Holman CD, Quadros CF, Bucens MR, Reid PM. Occurrence and distribution of hepatitis B infection in the Aboriginal population of Western Australia. Aust NZ J Med 1987;17(5):518–525.
Carroll E, Page W, Davis J. Screening for Hepatitis B in East Arnhem Land: a high prevalence of chronic infection despite incomplete screening. Int Med J. In press 2010.
Mintai Z, Kezhou L, Lieming D, Smego RA Jr. Duration and efficacy of immune response to hepatitis B vaccine in high-risk Chinese adolescents. Clin Infect Dis 1993;16(1):165–167.
Marion SA, Tomm Pastore M, Pi DW, Mathias RG. Long-term follow-up of hepatitis B vaccine in infants of carrier mothers. Am J Epidem 1994;140(8):734–746.
Lee PI, Lee CY, Huang LM, Chang MH. Long-term efficacy of recombinant hepatitis B vaccine and risk of natural infection in infants born to mothers with hepatitis B e antigen. J Pediatrics 1995;126(5 Pt 1):716–721.
Shannon C. Acculturation: Aboriginal and Torres Strait Islander nutrition. Asia Pacific J Clin Nutrition 2002;11 Suppl 3:S576–S578.
Belloni C, Chirico G, Pistorio A, Tinelli C, Rondini G. Immunogenicity of hepatitis B vaccine in term and preterm infants. Acta Paediatrica 1998;87(3):336–338.
Wilson JN, Nokes DJ, Carman WF. Predictions of the emergence of vaccine-resistant hepatitis B in The Gambia using a mathematical model. Epidemiol Infect 2000;124(2):295–307.
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2010 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
